Agent for the prevention, improvement or treatment of retinal disease

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9724312
APP PUB NO 20140128475A1
SERIAL NO

14154688

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which

    (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more,(b) consists of (5E,9E,13E)-geranylgeranylacetone, or(c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ROHTO PHARMACEUTICAL CO LTDOSAKA JAPAN OSAKA-SHI OSAKA

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kato, Mariyo Osaka, JP 7 30
Kurose, Takahiro Osaka, JP 32 151
Miyano, Takayuki Osaka, JP 18 57
Takai, Yoshihiro Osaka, JP 19 355

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 8, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 8, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00